Non-muscle-invasive bladder cancer is a highly prevalent disease and recurrences, after initial therapy, are common.
Consequently, the healthcare costs for non-muscle-invasive bladder cancer are high. Despite a primary adequate response to adjuvant intravesical treatment, many patients suffer from recurrences, and some even from progression. To date, cystectomy remains the only option for those non-responding patients with high risk of recurrence and progression. Mainly because outcome after progression, in this group, is poor. Therefore, new intravesical therapies are needed. Moreover, new accurate and individual parameters, to distinguish responder from non-responders, will provide additional benefit in clinical decision-making. In this review, current diagnostics and therapies will be discussed. In addition, we will elucidate developing therapies in non-muscle-invasive bladder cancer.
Written by:
van Lingen AV, Arends TJ, Witjes JA. Are you the author?
Department of Urology, Radboud University Medical Center, Geert Grooteplein zuid 10, 6525GA Nijmegen, The Netherlands.
Reference: Expert Rev Anticancer Ther. 2013 Nov;13(11):1257-68.
doi: 10.1586/14737140.2013.852474
PubMed Abstract
PMID: 24168049
UroToday.com Bladder Cancer Section
